In vitro · PMID 40493162
The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy — VialBase Research
Epitalon enhanced wound healing in diabetic retinopathy cell model
Last updated · 2025 · Gatta M, Dovizio M, Milillo C, et al. · Stem Cell Rev Rep
Key findings
- Epitalon enhanced wound healing in diabetic retinopathy cell model
- Mechanism involves antioxidant properties
- Addresses delayed healing in hyperglycemic conditions
- Extends epitalon applications beyond telomere/longevity to tissue repair
Epitalon Enhances Wound Healing in Diabetic Retinopathy (PMID: 40493162)
Study Design
- In vitro model of diabetic retinopathy (hyperglycemia-induced delayed wound healing)
- Treated with epitalon tetrapeptide
- Assessed wound healing capacity and antioxidant effects
Key Results
- Epitalon enhanced delayed wound healing in the diabetic retinopathy model
- Antioxidant properties identified as the primary mechanism
- Addresses the specific challenge of impaired healing under hyperglycemic stress
Relevance
Expands Epithalon‘s applications beyond telomere biology. The antioxidant and wound-healing properties are relevant to:
- Diabetic patients with impaired healing
- Retinal health in aging populations
- Broader tissue repair protocols
- Supports stacking with BPC-157 for enhanced healing
See Also
- Parent compound: Epithalon